David L. DeRemer

1.6k total citations
64 papers, 1.1k citations indexed

About

David L. DeRemer is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, David L. DeRemer has authored 64 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Hematology and 13 papers in Molecular Biology. Recurrent topics in David L. DeRemer's work include Chronic Lymphocytic Leukemia Research (8 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Multiple Myeloma Research and Treatments (5 papers). David L. DeRemer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Multiple Myeloma Research and Treatments (5 papers). David L. DeRemer collaborates with scholars based in United States, Georgia and Belgium. David L. DeRemer's co-authors include Celalettin Üstün, Payaningal R. Somanath, Kavita Natarajan, Belal Al‐Husein, Maha Abdalla, Cem Akin, Amber B. Clemmons, Farrukh T. Awan, Azza B. El‐Remessy and Susan C. Fagan and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David L. DeRemer

57 papers receiving 1.1k citations

Peers

Countries citing papers authored by David L. DeRemer

Since Specialization

Citations

This map shows the geographic impact of David L. DeRemer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. DeRemer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. DeRemer more than expected).

Fields of papers citing papers by David L. DeRemer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. DeRemer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. DeRemer. The network helps show where David L. DeRemer may publish in the future.

Co-authorship network of co-authors of David L. DeRemer

This figure shows the co-authorship network connecting the top 25 collaborators of David L. DeRemer. A scholar is included among the top collaborators of David L. DeRemer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. DeRemer. David L. DeRemer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Implementation of a pharmacogenetic panel‐based test for pharmacotherapy‐based supportive care in an adult oncology clinic 2024 ·Clinical and Translational Science ·Emily J. Cicali, Elizabeth M. Eddy, Yan Gong, (unknown), (unknown), (unknown), Karen Daily, (unknown), Steven M. Fischer, (unknown), Dennie V. Jones, Brian Hemendra Ramnaraign, David L. DeRemer, Thomas J. George, Rhonda M. Cooper‐DeHoff	1
2	Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms 2024 ·JCO Precision Oncology ·Thomas J. George, Ji‐Hyun Lee, David L. DeRemer, Peter J. Hosein, (unknown), Merry Jennifer Markham, Dennie V. Jones, Karen Daily, (unknown), Brian Hemendra Ramnaraign, Julia Close, (unknown), Martina Murphy, Carmen J. Allegra, (unknown), (unknown), (unknown), Gayathri Srinivasan, Montaser Shaheen, Robert Hromas	6
3	Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study). 2024 ·Journal of Clinical Oncology ·Thomas J. George, (unknown), Ibrahim Nassour, İlyas Şahin, Brian Hemendra Ramnaraign, Jesus C. Fabregas, Kathryn Hitchcock, (unknown), (unknown), Robert A. Zlotecki, Omar Kayaleh, Anita Turk, Z. Hugh Fan, Karen Russell, David L. DeRemer, Ji‐Hyun Lee, Steven J. Hughes	1
4	Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies 2023 ·Cancer Epidemiology Biomarkers & Prevention ·John M. Allen, (unknown), Yi Guo, Jiang Bian, (unknown), Lisa Scarton, David L. DeRemer, Diana J. Wilkie	3
5	Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline‐Based Chemotherapy 2023 ·Journal of the American Heart Association ·David L. DeRemer, (unknown), Avirup Guha, Faraz S. Ahmad, Rhonda M. Cooper‐DeHoff, Carl J. Pepine, Michael G. Fradley, Yan Gong	6
6	Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans 2023 ·Journal of the National Medical Association ·(unknown), David L. DeRemer, (unknown), Edward Agyare, John M. Allen, Luisel Ricks‐Santi, Bo Han, Thomas J. George, (unknown)	3
7	Immunotherapy Management in Special Cancer Patient Populations 2021 ·JCO Oncology Practice ·Brian Hemendra Ramnaraign, (unknown), Zeina Al‐Mansour, (unknown), Dennie V. Jones, David L. DeRemer, Thomas J. George	9
8	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center 2021 ·Cardio-Oncology ·Nida Waheed, Michael G. Fradley, David L. DeRemer, Ahmad Ahmad, Chintan Shah, Taimour Langaee, Gloria Lipori, Keith L. March, Carl J. Pepine, Rhonda M. Cooper‐DeHoff, Yonghui Wu, Yan Gong	29
9	National survey on the effect of oncology drug shortages in clinical practice: A Hematology Oncology Pharmacy Association (HOPA) survey. 2021 ·Journal of Clinical Oncology ·(unknown), David L. DeRemer, Larry W. Buie, (unknown), (unknown), Ali McBride	1
10	Abstract 15012: Lactate Dehydrogenase B and Pyruvate Oxidation Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: A Multi-omics Study 2020 ·Circulation ·(unknown), (unknown), Timothy J. Garrett, Sonal Singh, Chintan Shah, Michael G. Fradley, Robert F. Cornell, Rachid Baz, Nida Waheed, David L. DeRemer, Lihui Yuan, Taimour Langaee, Keith L. March, Carl J. Pepine, Jan S. Moreb, Yan Gong	1
11	Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors 2019 ·Journal of Oncology Pharmacy Practice ·(unknown), David L. DeRemer, (unknown), (unknown), Roni J. Bollag, Amber B. Clemmons	17
12	Pharmacy Student Performance in a Capstone Course Utilizing the Pharmacists’ Patient Care Process 2019 ·American Journal of Pharmaceutical Education ·Beth Bryles Phillips, Andrea Sikora, Christopher M. Bland, (unknown), (unknown), David L. DeRemer, (unknown)	28
13	The Importance of Research and Scholarly Activity in Pharmacy Training 2016 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Eli N. Deal, Paul M. Stranges, Whitney D. Maxwell, Jennifer L. Bacci, (unknown), David L. DeRemer, Sandra L. Kane‐Gill, Nicholas B. Norgard, (unknown), Robert B. Parker	49
14	Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia 2016 ·The Journal of Community and Supportive Oncology ·Abhishek A. Mangaonkar, Hongyan Xu, Mohsin Jamal, (unknown), (unknown), (unknown), David L. DeRemer, Amber B. Clemmons, Stephen M. Clark, (unknown), (unknown), Ravindra Kolhe, Vamsi Kota	3
15	Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies 2013 ·Bone Marrow Transplantation ·Farrukh T. Awan, Samith T. Kochuparambil, (unknown), Aaron Cumpston, (unknown), Katherine E. Watkins, David L. DeRemer, Anand Jillella, Michael Craig, Mehdi Hamadani	41
16	Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization 2012 ·Journal of Oncology ·Farrukh T. Awan, Samith T. Kochuparambil, David L. DeRemer, Aaron Cumpston, Michael Craig, Anand Jillella, Mehdi Hamadani	11
17	Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies 2012 ·Biology of Blood and Marrow Transplantation ·Mehdi Hamadani, Samith T. Kochuparambil, (unknown), Aaron Cumpston, (unknown), (unknown), Katherine E. Watkins, (unknown), (unknown), David L. DeRemer, Vamsi Kota, Anand Jillella, Michael Craig, Farrukh T. Awan	55
18	Tyrosine kinase inhibitors in the treatment of systemic mastocytosis 2011 ·Leukemia Research ·Celalettin Üstün, David L. DeRemer, Cem Akin	84
19	Investigational drugs targeting FLT3 for leukemia 2009 ·Expert Opinion on Investigational Drugs ·Celalettin Üstün, David L. DeRemer, Anand P. Jillella, Kapil N. Bhalla	12
20	Power-Frequency Electromagnetic Fields and the Capacitative Calcium Entry System in SV40-Transformed Swiss 3T3 Cells 2000 ·Radiation Research ·Jesse E. Sisken, David L. DeRemer	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact